Contineum Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Contineum Therapeutics, Inc. (NASDAQ: CTNM), formerly known as Pipeline Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with high unmet medical needs. The company's proprietary pipeline targets biological pathways associated with specific clinical impairments to fundamentally alter disease progression. Its lead wholly-owned asset is PIPE-791, a brain-penetrant lysophosphatidic acid 1 receptor (LPA1R) antagonist in clinical development for idiopathic pulmonary fibrosis (IPF) and chronic pain. Its second clinical-stage candidate is PIPE-307, a selective muscarinic M1 receptor antagonist partnered with Janssen Pharmaceutica NV (Johnson & Johnson) for the treatment of relapsing-remitting multiple sclerosis (RRMS) and major depressive disorder (MDD).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Contineum is maintaining a disciplined capital allocation strategy that prioritizes its lead clinical program, PIPE-791, for the treatment of idiopathic pulmonary fibrosis (IPF). To preserve capital and focus resources on the global Phase 2 PROPEL-IPF trial, the company made strategic decisions to defer further clinical development of its PIPE-791 progressive multiple sclerosis (PrMS) program and the initiation of clinical development for its CTX-343 program until specific external funding is secured.
Expected impact: Ensures sufficient financial runway to complete the Phase 2 IPF trial (estimated completion around 2028) without immediate dilutive financing needs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Co-developing and commercializing PIPE-307, a selective M1 receptor antagonist, for neurological and neuropsychiatric disorders including relapsing-remitting multiple sclerosis (RRMS) and major depressive disorder (MDD).
Terms: $50 million upfront payment received at inception (April 2023), with eligibility for up to approximately $1 billion in additional milestone payments plus royalties on commercial sales.